Report Categories
View AllRecent Articles
View All
NervGen Pharma Q3 2025 Earnings Narrowed Loss Meets Estimates But Stock Plunges 43
REG Q1 2026 Earnings Strong EPS Beat Drives Positive Investor Reaction
OPBK Q1 2026 Earnings EPS Surpasses Estimates by 146
LCID Q1 2026 Earnings EPS Miss Widens Amid Revenue Visibility Challenges
Immunome Q1 2026 Earnings NarrowerThanExpected Loss as Pipeline Progress Continues